He Meilian, Guo Changchuan, Leng Jiawei, Zhang Xunjie, Xian Ruiqing, Gong Liping, Shi Feng, Jiang Wei
School of Pharmaceutical Sciences, Shandong University, Jinan 250012, China.
Shandong Institute for Food and Drug Control, Jinan 250101, China.
Se Pu. 2018 Nov 1;36(11):1099-1104. doi: 10.3724/SP.J.1123.2018.07021.
A rapid, simple and sensitive ultra high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) method was developed for the determination of ambroxol hydrochloride in human plasma, and bioequivalence of its preparation was evaluated. The 50 μL-plasma sample was treated with methanol for protein precipitation, while ambroxol-d5 was used as an internal standard (IS). The separation was carried out on a Waters XBridge BEH C18 column (50 mm×2.1 mm, 2.5 μm) by gradient elution at a flow rate of 0.4 mL/min, with 0.1% (v/v) formic acid aqueous solution and methanol containing 0.1% (v/v) formic acid as the mobile phases. The analyte was detected using an electrospray ionization source in positive ion multiple reaction monitoring (MRM) mode. The calibration curves were linear in the range of 2-400 ng/mL (=0.998). The intra- and inter-run accuracies were 97.1%-108.7%, the intra- and inter-run precisions were 1.0%-5.6%. The method was applied to the determination of the plasma concentration of the six healthy subjects after the oral administration of 30 mg of test and reference preparations. The bioavailability was (102.3±14.8)%. The 90% confidence intervals of the test preparation's pharmacokinetic parameters were 80.0%-125.0% of the reference preparation's corresponding parameters. Thus, it is proved that the test preparation and reference preparation are bioequivalent.
建立了一种快速、简单且灵敏的超高效液相色谱 - 串联质谱法(UHPLC - MS/MS)用于测定人血浆中盐酸氨溴索,并评价其制剂的生物等效性。取50 μL血浆样品,用甲醇进行蛋白沉淀,同时使用氨溴索 - d5作为内标(IS)。采用Waters XBridge BEH C18柱(50 mm×2.1 mm,2.5 μm)进行分离,以0.4 mL/min的流速梯度洗脱,流动相为含0.1%(v/v)甲酸的水溶液和含0.1%(v/v)甲酸的甲醇。采用电喷雾电离源在正离子多反应监测(MRM)模式下检测分析物。校准曲线在2 - 400 ng/mL范围内呈线性(r = 0.998)。批内和批间准确度为97.1% - 108.7%,批内和批间精密度为1.0% - 5.6%。该方法应用于6名健康受试者口服30 mg受试制剂和参比制剂后血浆浓度的测定。生物利用度为(102.3±14.8)%。受试制剂药代动力学参数的90%置信区间为参比制剂相应参数的80.0% - 125.0%。因此,证明受试制剂和参比制剂具有生物等效性。